Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
The potential benefit of drug therapy for prehypertension and the cardiometabolic syndrome has previously not been confirmed. This case represents a patient who may show slowing or avoiding progression from prehypertension to hypertension based on recent trial evidence and assists the clinician in identifying the risk associated with blood pressure elevation before a conventional cut point of 140/90 mm Hg.
Heartbeats Life Center, New Orleans, LA, USA. kcferdmd@aol.com
Keith C
KC
Ferdinand
D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors
D000959:Antihypertensive Agents